A PhI­II Tecen­triq win? Not so much, it turns out, as Roche spells out weak da­ta on blad­der can­cer

When Roche first top-lined their IMvig­or130 study a cou­ple of months ago, com­pa­ny ex­ecs called it the “first pos­i­tive Phase III study of a can­cer im­munother­a­py com­bi­na­tion in pre­vi­ous­ly un­treat­ed ad­vanced blad­der can­cer.” The study, they said in trum­pet­ing the suc­cess, hit the co-pri­ma­ry on pro­gres­sion-free sur­vival.

But they were be­ing kind to them­selves.

Over the week­end at ES­MO its own in­ves­ti­ga­tors said they don’t be­lieve they could like­ly gain an ap­proval with the da­ta in Tecen­tri com­bined with chemo — which are weak.

In­ves­ti­ga­tor Igna­cio Durán “cau­tioned that this im­prove­ment in pro­gres­sion free sur­vival may be in­suf­fi­cient for reg­u­la­to­ry ap­proval at this stage, but said the da­ta look promis­ing,” reads ES­MO’s state­ment on the da­ta.

Hard­ly a ring­ing en­dorse­ment.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER